Trials / Completed
CompletedNCT00217139
A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection
A Phase II, Randomized, Active-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Celgosivir in Combination With Peginterferon Alfa-2b, With and Without Ribavirin, for 12 Weeks in Patients With Chronic Hepatitis C Infection (Genotype 1) Who Failed to Respond to Pegylated α Interferon-Based Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- BioWest Therapeutics Inc · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to evaluate the safety and efficacy of celgosivir plus peginterferon alfa-2b, with or without ribavirin, for 12 weeks in patients with chronic hepatitis C genotype 1 infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Celgosivir |
Timeline
- Start date
- 2005-09-01
- Completion
- 2006-09-01
- First posted
- 2005-09-22
- Last updated
- 2006-09-29
Locations
6 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00217139. Inclusion in this directory is not an endorsement.